无创正压通气与重症哮喘急性发作临床结局的关联:一项队列研究
该回顾性倾向评分匹配队列研究利用2006-2019年纽约和佛罗里达州住院数据库,纳入5-80岁因哮喘急性发作住院的患者。2006至2018年间,成人无创正压通气使用率从1.2%升至7.4%,儿童从0.7%升至7.1%。在41,902例ICU encounters中匹配后分析显示,成人使用无创正压通气与后续插管风险降低(RR 0.48;95%CI 0.40-0.57)及院内死亡率改善(RR 0.33;95%CI 0.21-0.54)相关;儿童使用与插管风险降低相关(RR 0.50;95%CI 0.29-0.89),但院内死亡率改善无统计学意义(RR 0.41;95%CI 0.15-1.11)。
要点
- 成人重症哮喘急性发作使用无创正压通气与后续插管风险降低相关(RR 0.48;95%CI 0.40-0.57)。
- 成人使用无创正压通气与院内死亡率改善相关(RR 0.33;95%CI 0.21-0.54)。
- 儿童使用无创正压通气与插管风险降低相关(RR 0.50;95%CI 0.29-0.89),院内死亡率改善无统计学意义(RR 0.41;95%CI 0.15-1.11)。
- 2006至2018年成人无创正压通气使用率从1.2%升至7.4%(绝对差6.1%;95%CI 5.6-6.7%),儿童从0.7%升至7.1%(绝对差6.4%;95%CI 5.5-7.3%)。
适用人群与场景
- 5-80岁因哮喘急性发作住院的患者,数据来自纽约和佛罗里达州住院数据库2006-2019年。
- ICU encounters共41,902例,匹配后分析成人无创正压通气组1,972例与未使用组6,510例,儿童无创正压通气组1,622例与未使用组4,766例。
研究设计与关键结果
- 研究类型:回顾性、倾向评分匹配队列研究,使用2006-2019年纽约和佛罗里达州住院数据库行政数据。
- 2006至2018年共296,788例哮喘急性发作住院,成人无创正压通气使用率从1.2%升至7.4%(绝对差6.1%;95%CI 5.6-6.7%),儿童从0.7%升至7.1%(绝对差6.4%;95%CI 5.5-7.3%)。
- 成人使用无创正压通气与后续插管风险降低相关(RR 0.48;95%CI 0.40-0.57),与院内死亡率改善相关(RR 0.33;95%CI 0.21-0.54)。
- 儿童使用无创正压通气与插管风险降低相关(RR 0.50;95%CI 0.29-0.89),院内死亡率改善无统计学意义(RR 0.41;95%CI 0.15-1.11)。
证据类型、等级与局限
- 证据类型:回顾性、倾向评分匹配队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,成人和儿童哮喘急性发作使用无创正压通气与气管插管风险降低相关,成人还与院内死亡率改善相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The evidence supporting the use of noninvasive positive pressure ventilation (NPPV) during severe asthma exacerbations is limited. We determined the annual trend in NPPV use, endotracheal intubations, and in-hospital mortality among all hospitalizations for an asthma exacerbation. We additionally evaluated the association between NPPV use and subsequent endotracheal intubation and in-hospital mortality.
DESIGN: Retrospective, propensity-score-matched cohort study.
SETTING: Administrative data from Healthcare Cost and Utilization Project's State Inpatient Databases for New York and Florida, 2006-2019.
PATIENTS: Patients 5-80 years old hospitalized with an asthma exacerbation.
INTERVENTIONS: Receipt of NPPV.
MEASUREMENTS AND MAIN RESULTS: Among 296,788 hospitalizations for an asthma exacerbation between 2006 and 2018, NPPV use for an asthma exacerbation increased from 1.2% to 7.4% (absolute difference, 6.1%; 95% CI, 5.6-6.7%) in adults and from 0.7% to 7.1% (absolute difference, 6.4%; 95% CI, 5.5-7.3%) in pediatric patients. Among 41,902 ICU encounters, we propensity-score matched 1,972 adult and 1,622 pediatric patients who received NPPV with 6,510 adults and 4,766 pediatric patients who did not receive NPPV. NPPV use was associated with a decreased risk of subsequent intubation (risk ratio [RR], 0.48; 95% CI, 0.40-0.57) and improved in-hospital mortality (RR, 0.33; 95% CI, 0.21-0.54) in adults. In pediatric patients, use of NPPV was associated with a decreased risk of intubation (RR, 0.50; 95% CI, 0.29-0.89), but not significant for an improvement in in-hospital mortality (RR, 0.41; 95% CI, 0.15-1.11).
CONCLUSIONS: NPPV use for asthma exacerbations has increased. In adult and pediatric patients, NPPV use for an asthma exacerbation was associated with a decreased risk of endotracheal intubation. Furthermore, NPPV use for an asthma exacerbation was associated with improved in-hospital mortality in adult patients.
参考来源
- Abbott MR, Carpenter KP, Razi S, et al. Association Between Noninvasive Positive Pressure Ventilation Use and Clinical Outcomes During a Severe Asthma Exacerbation: A Cohort Study. Crit Care Med. 2026. PMID: 41532815. doi:10.1097/CCM.0000000000007025
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。